Whirlpool Corp /De/
$8.15B- Market cap
- $2.30B
- Debt
- +$6.52B
- Cash
- −$669.00M
Capital structure 26% equity / 74% debt · EV / Revenue 0.52x · EV proxy / EBITDA proxy 6.93x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: WHR stock price vs ZNTL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ZNTL's multiple
Needs ZNTL P/E.
Implied fair value · at WHR's multiple
Needs Annual EPS is negative.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 26% equity / 74% debt · EV / Revenue 0.52x · EV proxy / EBITDA proxy 6.93x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
WHIRLPOOL CORP /DE/ · implied price per share
Bear
-$46.25
Base
-$39.05
Bull
-$26.28
Zentalis Pharmaceuticals, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BEST BUY CO INC
WHR vs BBY
HOME DEPOT, INC.
WHR vs HD
GENERAL ELECTRIC CO
WHR vs GE
HELEN OF TROY LTD
WHR vs HELE
NEWELL BRANDS INC.
WHR vs NWL
Spectrum Brands Holdings, Inc.
WHR vs SPB
Arcus Biosciences, Inc.
WHR vs RCUS
Repare Therapeutics Inc.
WHR vs RPTX
IDEAYA Biosciences, Inc.
WHR vs IDYA
Mersana Therapeutics, Inc.
WHR vs MRSN
EXELIXIS, INC.
WHR vs EXEL
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe WHR can stabilize revenue and manage its leverage while maintaining positive margins, then favor WHR over ZNTL because WHR is profitable, trades at far lower P/S and EV/Revenue multiples, and sits below the DCF range despite only moderate quality concerns.
WHR trades at a deep discount on earnings- and sales-based metrics versus ZNTL's much richer sales multiple, but the implied price of $1293.37 is mechanically inflated by applying ZNTL's P/S to WHR. WHR also sits near the midpoint of its historical band at $38.10, while the DCF range of $92.12 to $124.63 suggests materially higher intrinsic value than the current price.
Supporting Metrics